Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Allarity Therapeutics Receives Acceptance & Review Notification from U.S. FDA for Pre-Market Approval Application for Dovitinib-DRP

firstwordpharmaJuly 06, 2021

Tag: Allarity , Dovitinib-DRP , PMA

PharmaSources Customer Service